NDAORALTABLET, EXTENDED RELEASE
Approved
Aug 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
WELLBUTRIN XL (bupropion hydrochloride) by Bausch + Lomb is unknown, as is the case with other antidepressants. Approved for major depressive disorder (mdd), defined by the diagnostic, statistical manual (dsm) and 1 more indications. First approved in 2003.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Wellbutrin XL is an extended-release formulation of bupropion hydrochloride, an oral antidepressant indicated for major depressive disorder. It works as a norepinephrine-dopamine reuptake inhibitor (NDRI), distinguishing it mechanistically from SSRIs and SNRIs. The XL formulation allows once-daily dosing for improved patient compliance.
$77MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D spending signals a mature, stable franchise in managed decline requiring defensive commercial strategies.
Mechanism of Action
unknown, as is the case with other antidepressants. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the…
Indications (4)
Worked on WELLBUTRIN XL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.